美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CLDX近 30 天 1 則 · 第 1 / 1 頁
- Celldex to Present at Upcoming Investor Conference
- Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
- Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?
- Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
- What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?
- Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
- Celldex Reports Second Quarter Financial Results and Provides Corporate Update
- Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
- Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
- CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
- Celldex Announces Planned Transition of Chief Financial Officer
- Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
- Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
- QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
- Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
- Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。